英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

solarize    
vt. 使过度曝光,晒
vi. 曝光

使过度曝光,晒曝光

solarize
v 1: reverse some of the tones of (a negative or print) and
introduce pronounced outlines of highlights, by exposing it
briefly to light, then washing and redeveloping it [synonym:
{solarize}, {solarise}]
2: become overexposed; "The film solarized" [synonym: {solarize},
{solarise}]
3: overexpose to sunlight; "be careful not to solarize the
photographic film" [synonym: {solarize}, {solarise}]
4: expose to the rays of the sun or affect by exposure to the
sun; "insolated paper may turn yellow and crumble"; "These
herbs suffer when sunned" [synonym: {sun}, {insolate},
{solarize}, {solarise}]


请选择你想看的字典辞典：
单词字典翻译
solarize查看　solarize　在百度字典中的解释百度英翻中〔查看〕
solarize查看　solarize　在Google字典中的解释Google英翻中〔查看〕
solarize查看　solarize　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • LIBTAYO® Full Prescribing Information | Regeneron
    LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6
  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • Libtayo - European Medicines Agency (EMA)
    Overview Libtayo is a cancer medicine used in adults to treat: a type of skin cancer called cutaneous squamous cell carcinoma It is used on its own in adults who cannot have surgery or treatment with radiation to cure their disease when the cancer is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body)
  • Libtayo (Cemiplimab-rwlc Injection): Side Effects, Uses . . .
    Libtayo (Cemiplimab-rwlc Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources
  • FDA Approves Cemiplimab as Adjuvant Treatment for Cutaneous . . .
    Cemiplimab's approval is supported by findings from the C-POST clinical trial The FDA approved cemiplimab-rwlc (Libtayo; Regeneron Pharmaceuticals) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) who are at a high risk of recurrence following surgery and radiation
  • Libtayo (cemiplimab-rwlc) for Skin Cancer: Side Effects Dosage
    Libtayo (cemiplimab-rwlc) is a prescription medication used to treat a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation The most common side effects of Libtayo include tiredness, rash, diarrhea, muscle or bone pain, and nausea
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    The approval was based on the C-POST study which evaluated cemiplimab in adults with CSCC at high risk of recurrence after surgery and radiation





中文字典-英文字典  2005-2009